Efficacy and Safety of Phosphodiesterase-4 Inhibitors in Vitiligo: A Systematic Review
Published: 31 December 2024| Version 1 | DOI: 10.17632/k8byncrz2f.1
Contributor:
Reya HanspalDescription
Vitiligo is a chronic autoimmune disorder characterized by melanocyte destruction, loss of pigmented melanin and resultant non-scaly white macules. Treatment modalities are aimed at controlling disease progression, and begin with topical and systemic steroids, calcineurin inhibitors, immunosuppressants, and narrowband ultraviolet B (UVB) phototherapy. This systematic review summarizes and identifies the treatment outcomes of phosphodiesterase-4 inhibitors (PDE4i), an emerging therapy, for the treatment of vitiligo.
Files
Institutions
Queen's University
Categories
Dermatology, Vitiligo